TickerGuard
Buy Day today: Neutral (57) Mixed market breadth · no major macro event
HRTX

Heron Therapeuti

Healthcare · Biotechnology

0.4061$ +13.4% vs. previous close Closing price · As of: Oct 9, 2026

Statements

Balance Sheet

Heron Therapeuti (HRTX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 252 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios
Annual Quarterly
Amounts Change % Common size %
Last 12 Full history
Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet HRTX
Line item Q3 16 Q4 16 Q1 17 Q2 17 Q3 17 Q4 17 Q1 18 Q2 18 Q3 18 Q4 18 Q1 19 Q2 19 Q3 19 Q4 19 Q1 20 Q2 20 Q3 20 Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
99 67 190 142 118 234 183 511 471 462 436 412 393 513 479 433 390 354 311 404 352 306 274 244 272 251 221 201 229 223 218 218 221 233 236 232 249 256 246 252
94 62 184 136 113 228 177 503 460 447 406 381 364 479 438 393 351 314 272 367 315 254 223 194 224 205 178 165 194 189 186 191 195 209 213 211 229 238 229 230
46 13 84 30 66 145 47 259 54 32 23 53 60 72 103 81 95 105 60 191 160 91 57 49 50 15 27 13 35 29 20 18 26 26 19 17 43 29 26 21
89 51 165 109 74 172 114 423 365 332 289 276 256 391 356 301 258 208 166 258 203 158 112 84 122 85 60 33 77 80 72 67 71 59 51 41 55 47 45 43
-3.1 2.0 10 19 29 42 38 46 54 65 74 67 67 40 35 38 34 42 39 43 43 35 41 40 42 52 51 77 64 60 65 74 67 79 79 80 81 90 84 90
2.0 5.3 4.6 4.8 5.2 10 19 27 31 39 31 29 24 25 35 41 43 42 43 43 42 48 56 61 52 55 52 45 42 42 42 43 46 53 57 73 70 93 93 91
4.7 5.1 5.7 5.8 5.3 6.0 6.5 7.5 11 15 16 18 16 20 22 22 22 23 23 37 23 34 24 32 31 30 22 21 27 – – – – – – – – – – –
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – –
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – –
81 89 87 73 78 103 91 79 64 92 104 106 108 109 113 109 113 117 115 244 234 228 250 266 250 237 232 241 257 256 252 256 261 267 264 259 234 242 237 245
31 39 37 48 53 103 91 79 64 92 92 95 97 97 97 93 98 103 101 82 72 71 93 109 94 82 78 87 80 80 75 80 86 91 89 259 90 96 91 92
2.7 2.9 3.1 3.3 3.5 29 29 29 4.3 4.6 8.9 8.5 8.8 7.6 8.7 9.1 9.5 10 11 3.2 3.3 2.4 2.5 2.5 2.6 2.7 2.8 2.6 3.0 3.1 3.1 3.2 3.2 3.0 2.3 177 0.8 – – 0.2
6.1 6.8 4.5 6.3 5.3 19 11 5.0 9.6 17 11 8.0 1.6 3.1 12 18 12 0.6 1.7 11 5.9 3.9 8.2 14 6.5 3.6 4.1 2.0 1.9 3.8 0.8 10 10 12 12 12 12 9.0 9.0 12
50 50 50 25 25 0.0 0.0 0.0 0.0 – 12 – – – – – – – – 149 149 149 149 149 149 149 149 149 173 174 174 174 174 175 175 – 140 141 142 143
18 -21 102 69 40 131 92 432 407 370 332 305 285 404 365 324 277 236 196 160 119 78 24 -22 22 14 -11 -39 -28 -34 -34 -38 -40 -34 -28 -27 15 14 9.1 6.9
-538 -586 -636 -679 -721 -783 -834 -873 -911 -961 -1,024 -1,074 -1,108 -1,165 -1,217 -1,272 -1,330 -1,393 -1,445 -1,506 -1,559 -1,613 -1,677 -1,734 -1,776 -1,795 -1,828 -1,870 -1,895 -1,906 -1,909 -1,918 -1,923 -1,920 -1,917 -1,919 -1,937 -1,940 -1,948 -1,953
39 39 51 54 54 65 65 72 78 78 78 80 80 89 90 91 91 91 91 98 102 102 102 102 112 119 119 120 145 150 151 152 153 153 153 154 170 167 190 190

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?